Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

Detected CMS Systems:

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1186/bcr3444.

Title:
BreastMark: An Integrated Approach to Mining Publicly Available Transcriptomic Datasets Relating to Breast Cancer Outcome | Breast Cancer Research
Description:
Introduction Breast cancer is a complex heterogeneous disease for which a substantial resource of transcriptomic data is available. Gene expression data have facilitated the division of breast cancer into, at least, five molecular subtypes, namely luminal A, luminal B, HER2, normal-like and basal. Once identified, breast cancer subtypes can inform clinical decisions surrounding patient treatment and prognosis. Indeed, it is important to identify patients at risk of developing aggressive disease so as to tailor the level of clinical intervention. Methods We have developed a user-friendly, web-based system to allow the evaluation of genes/microRNAs (miRNAs) that are significantly associated with survival in breast cancer and its molecular subtypes. The algorithm combines gene expression data from multiple microarray experiments which frequently also contain miRNA expression information, and detailed clinical data to correlate outcome with gene/miRNA expression levels. This algorithm integrates gene expression and survival data from 26 datasets on 12 different microarray platforms corresponding to approximately 17,000 genes in up to 4,738 samples. In addition, the prognostic potential of 341 miRNAs can be analysed. Results We demonstrated the robustness of our approach in comparison to two commercially available prognostic tests, oncotype DX and MammaPrint. Our algorithm complements these prognostic tests and is consistent with their findings. In addition, BreastMark can act as a powerful reductionist approach to these more complex gene signatures, eliminating superfluous genes, potentially reducing the cost and complexity of these multi-index assays. Known miRNA prognostic markers, mir-205 and mir-93, were used to confirm the prognostic value of this tool in a miRNA setting. We also applied the algorithm to examine expression of 58 receptor tyrosine kinases in the basal-like subtype, identifying six receptor tyrosine kinases associated with poor disease-free survival and/or overall survival (EPHA5, FGFR1, FGFR3, VEGFR1, PDGFRβ, and TIE1). A web application for using this algorithm is currently available. Conclusions BreastMark is a powerful tool for examining putative gene/miRNA prognostic markers in breast cancer. The value of this tool will be in the preliminary assessment of putative biomarkers in breast cancer. It will be of particular use to research groups with limited bioinformatics facilities.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Education
  • Science
  • Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?


Link.springer.com operates using PLONE.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 7,625,932 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

cancer, breast, pubmed, gene, expression, article, google, scholar, survival, genes, data, prognostic, cas, markers, prognosis, patients, breastmark, signature, central, mirnas, clinical, molecular, receptor, poor, table, datasets, subtypes, oncotype, algorithm, analysis, approach, outcome, subtype, profiling, res, information, results, research, patient, mammaprint, microrna, human, host, high, basal, samples, nature, score, mirna, tyrosine,

Topics {✒️}

org/packages/release/bioc/html/genefu gene-centred survival meta-analysis endocrine-responsive breast cancer article download pdf erbb2-amplified breast cancers full access node-negative breast cancer microrna expression profiling large-scale coexpression analysis microrna expression profiles disease/tissue specific manner triple-negative breast cancer breast tumor subtypes gene/mirna expression levels avoid dataset-specific affects mentioned survival end-points distant disease-free survival large-scale robust signature biomart central portal kaplan-meier survival curve tumour size potential drug targets open database network predicts patient outcome simple user-friendly tool clinical cancer research colin clarke gene expression profiling gene expression profiles gene-expression profiles negate study-specific effects breast cancer research related subjects lymph node-negative poor disease-free survival predicting patient prognosis complex gene signatures incorporate mirna profiling microrna profiling breast cancer outcome author information authors breast cancer recurrence privacy choices/manage cookies complex heterogeneous disease detailed clinical data breast cancer based gene expression data lymph node status complex prognostic signatures tumor subtype

Questions {❓}

  • Allison KH, Kandalaft PL, Sitlani CM, Dintzis SM, Gown AM: Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing?
  • Lee JJ, Shen J: Is the Oncotype DX assay necessary in strongly estrogen receptor-positive breast cancers?
  • Paik S: Is gene array testing to be considered routine now?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:BreastMark: An Integrated Approach to Mining Publicly Available Transcriptomic Datasets Relating to Breast Cancer Outcome
         description:Breast cancer is a complex heterogeneous disease for which a substantial resource of transcriptomic data is available. Gene expression data have facilitated the division of breast cancer into, at least, five molecular subtypes, namely luminal A, luminal B, HER2, normal-like and basal. Once identified, breast cancer subtypes can inform clinical decisions surrounding patient treatment and prognosis. Indeed, it is important to identify patients at risk of developing aggressive disease so as to tailor the level of clinical intervention. We have developed a user-friendly, web-based system to allow the evaluation of genes/microRNAs (miRNAs) that are significantly associated with survival in breast cancer and its molecular subtypes. The algorithm combines gene expression data from multiple microarray experiments which frequently also contain miRNA expression information, and detailed clinical data to correlate outcome with gene/miRNA expression levels. This algorithm integrates gene expression and survival data from 26 datasets on 12 different microarray platforms corresponding to approximately 17,000 genes in up to 4,738 samples. In addition, the prognostic potential of 341 miRNAs can be analysed. We demonstrated the robustness of our approach in comparison to two commercially available prognostic tests, oncotype DX and MammaPrint. Our algorithm complements these prognostic tests and is consistent with their findings. In addition, BreastMark can act as a powerful reductionist approach to these more complex gene signatures, eliminating superfluous genes, potentially reducing the cost and complexity of these multi-index assays. Known miRNA prognostic markers, mir-205 and mir-93, were used to confirm the prognostic value of this tool in a miRNA setting. We also applied the algorithm to examine expression of 58 receptor tyrosine kinases in the basal-like subtype, identifying six receptor tyrosine kinases associated with poor disease-free survival and/or overall survival (EPHA5, FGFR1, FGFR3, VEGFR1, PDGFRβ, and TIE1). A web application for using this algorithm is currently available. BreastMark is a powerful tool for examining putative gene/miRNA prognostic markers in breast cancer. The value of this tool will be in the preliminary assessment of putative biomarkers in breast cancer. It will be of particular use to research groups with limited bioinformatics facilities.
         datePublished:2013-07-02T00:00:00Z
         dateModified:2013-07-02T00:00:00Z
         pageStart:1
         pageEnd:14
         license:http://creativecommons.org/licenses/by/2.0/
         sameAs:https://doi.org/10.1186/bcr3444
         keywords:
            Breast Cancer
            Overall Survival
            Gene Expression Data
            Recurrence Score
            Breast Cancer Dataset
            Cancer Research
            Oncology
            Surgical Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3444/MediaObjects/13058_2012_3278_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3444/MediaObjects/13058_2012_3278_Fig2_HTML.jpg
         isPartOf:
            name:Breast Cancer Research
            issn:
               1465-542X
            volumeNumber:15
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Stephen F Madden
               affiliation:
                     name:Dublin City University
                     address:
                        name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Colin Clarke
               affiliation:
                     name:Dublin City University
                     address:
                        name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Patricia Gaule
               affiliation:
                     name:Dublin City University
                     address:
                        name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sinead T Aherne
               affiliation:
                     name:Dublin City University
                     address:
                        name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Norma O'Donovan
               affiliation:
                     name:Dublin City University
                     address:
                        name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Martin Clynes
               affiliation:
                     name:Dublin City University
                     address:
                        name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:John Crown
               affiliation:
                     name:Dublin City University
                     address:
                        name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:William M Gallagher
               affiliation:
                     name:University College Dublin
                     address:
                        name:UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin 4, Ireland
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:BreastMark: An Integrated Approach to Mining Publicly Available Transcriptomic Datasets Relating to Breast Cancer Outcome
      description:Breast cancer is a complex heterogeneous disease for which a substantial resource of transcriptomic data is available. Gene expression data have facilitated the division of breast cancer into, at least, five molecular subtypes, namely luminal A, luminal B, HER2, normal-like and basal. Once identified, breast cancer subtypes can inform clinical decisions surrounding patient treatment and prognosis. Indeed, it is important to identify patients at risk of developing aggressive disease so as to tailor the level of clinical intervention. We have developed a user-friendly, web-based system to allow the evaluation of genes/microRNAs (miRNAs) that are significantly associated with survival in breast cancer and its molecular subtypes. The algorithm combines gene expression data from multiple microarray experiments which frequently also contain miRNA expression information, and detailed clinical data to correlate outcome with gene/miRNA expression levels. This algorithm integrates gene expression and survival data from 26 datasets on 12 different microarray platforms corresponding to approximately 17,000 genes in up to 4,738 samples. In addition, the prognostic potential of 341 miRNAs can be analysed. We demonstrated the robustness of our approach in comparison to two commercially available prognostic tests, oncotype DX and MammaPrint. Our algorithm complements these prognostic tests and is consistent with their findings. In addition, BreastMark can act as a powerful reductionist approach to these more complex gene signatures, eliminating superfluous genes, potentially reducing the cost and complexity of these multi-index assays. Known miRNA prognostic markers, mir-205 and mir-93, were used to confirm the prognostic value of this tool in a miRNA setting. We also applied the algorithm to examine expression of 58 receptor tyrosine kinases in the basal-like subtype, identifying six receptor tyrosine kinases associated with poor disease-free survival and/or overall survival (EPHA5, FGFR1, FGFR3, VEGFR1, PDGFRβ, and TIE1). A web application for using this algorithm is currently available. BreastMark is a powerful tool for examining putative gene/miRNA prognostic markers in breast cancer. The value of this tool will be in the preliminary assessment of putative biomarkers in breast cancer. It will be of particular use to research groups with limited bioinformatics facilities.
      datePublished:2013-07-02T00:00:00Z
      dateModified:2013-07-02T00:00:00Z
      pageStart:1
      pageEnd:14
      license:http://creativecommons.org/licenses/by/2.0/
      sameAs:https://doi.org/10.1186/bcr3444
      keywords:
         Breast Cancer
         Overall Survival
         Gene Expression Data
         Recurrence Score
         Breast Cancer Dataset
         Cancer Research
         Oncology
         Surgical Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3444/MediaObjects/13058_2012_3278_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3444/MediaObjects/13058_2012_3278_Fig2_HTML.jpg
      isPartOf:
         name:Breast Cancer Research
         issn:
            1465-542X
         volumeNumber:15
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Stephen F Madden
            affiliation:
                  name:Dublin City University
                  address:
                     name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Colin Clarke
            affiliation:
                  name:Dublin City University
                  address:
                     name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Patricia Gaule
            affiliation:
                  name:Dublin City University
                  address:
                     name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sinead T Aherne
            affiliation:
                  name:Dublin City University
                  address:
                     name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Norma O'Donovan
            affiliation:
                  name:Dublin City University
                  address:
                     name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Martin Clynes
            affiliation:
                  name:Dublin City University
                  address:
                     name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:John Crown
            affiliation:
                  name:Dublin City University
                  address:
                     name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:William M Gallagher
            affiliation:
                  name:University College Dublin
                  address:
                     name:UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin 4, Ireland
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research
      issn:
         1465-542X
      volumeNumber:15
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Dublin City University
      address:
         name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
         type:PostalAddress
      name:Dublin City University
      address:
         name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
         type:PostalAddress
      name:Dublin City University
      address:
         name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
         type:PostalAddress
      name:Dublin City University
      address:
         name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
         type:PostalAddress
      name:Dublin City University
      address:
         name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
         type:PostalAddress
      name:Dublin City University
      address:
         name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
         type:PostalAddress
      name:Dublin City University
      address:
         name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
         type:PostalAddress
      name:University College Dublin
      address:
         name:UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin 4, Ireland
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Stephen F Madden
      affiliation:
            name:Dublin City University
            address:
               name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Colin Clarke
      affiliation:
            name:Dublin City University
            address:
               name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
               type:PostalAddress
            type:Organization
      name:Patricia Gaule
      affiliation:
            name:Dublin City University
            address:
               name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
               type:PostalAddress
            type:Organization
      name:Sinead T Aherne
      affiliation:
            name:Dublin City University
            address:
               name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
               type:PostalAddress
            type:Organization
      name:Norma O'Donovan
      affiliation:
            name:Dublin City University
            address:
               name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
               type:PostalAddress
            type:Organization
      name:Martin Clynes
      affiliation:
            name:Dublin City University
            address:
               name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
               type:PostalAddress
            type:Organization
      name:John Crown
      affiliation:
            name:Dublin City University
            address:
               name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
               type:PostalAddress
            type:Organization
      name:William M Gallagher
      affiliation:
            name:University College Dublin
            address:
               name:UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin 4, Ireland
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
      name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
      name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
      name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
      name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
      name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
      name:Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
      name:UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin 4, Ireland

External Links {🔗}(250)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

5.41s.